MedTrace Logo

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

NCT03272464 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-09-22

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of drugs as a possible treatment for BRAF-mutant melanoma.

The drugs involved in this study are:

* Itacitinib (INCB039110)
* Dabrafenib
* Trametinib

Conditions

Interventions

DRUG

Trametinib

Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.

DRUG

Dabrafenib

Dabrafenib may work by stopping your cancer cells from duplicating.

DRUG

INCB039110

Itacitinib may work by stopping your tumor cells from living and growing.

Sponsors & Collaborators

Principal Investigators

  • David M. Miller, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2019-07-24
Completion
2019-12-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03272464 on ClinicalTrials.gov